Wedbush reissued their outperform rating on shares of Intellia Therapeutics Inc (NASDAQ:NTLA) in a research note published on Wednesday, May 3rd. Wedbush currently has a $25.00 price objective on the stock.

A number of other brokerages also recently issued reports on NTLA. Jefferies Group LLC set a $33.00 price target on Intellia Therapeutics and gave the stock a buy rating in a research report on Wednesday, January 11th. Zacks Investment Research raised Intellia Therapeutics from a sell rating to a hold rating in a report on Tuesday, April 18th. Leerink Swann reissued an outperform rating on shares of Intellia Therapeutics in a research note on Thursday, January 5th. Finally, Chardan Capital initiated coverage on Intellia Therapeutics in a research report on Monday, March 27th. They set a buy rating and a $19.00 price target for the company. They noted that the move was a valuation call. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Intellia Therapeutics has a consensus rating of Buy and an average target price of $25.29.

Intellia Therapeutics (NASDAQ:NTLA) traded up 0.3749% on Wednesday, reaching $14.4038. 25,804 shares of the company’s stock traded hands. The firm’s market cap is $518.94 million. The firm’s 50-day moving average is $14.22 and its 200 day moving average is $14.26. Intellia Therapeutics has a 12 month low of $10.83 and a 12 month high of $30.40.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings results on Tuesday, May 2nd. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by $0.02. The business had revenue of $6.22 million during the quarter, compared to the consensus estimate of $5.30 million. Equities analysts predict that Intellia Therapeutics will post ($1.45) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Intellia Therapeutics’ (NTLA) “Outperform” Rating Reiterated at Wedbush” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was stolen and reposted in violation of US & international trademark & copyright laws. The correct version of this piece of content can be viewed at

In other news, Director Jean Francois Formela sold 21,132 shares of the company’s stock in a transaction on Friday, March 10th. The stock was sold at an average price of $13.91, for a total transaction of $293,946.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

A number of large investors have recently added to or reduced their stakes in the company. Atlas Venture Associates IX LLC purchased a new stake in shares of Intellia Therapeutics during the fourth quarter valued at approximately $58,075,000. Baker BROS. Advisors LP bought a new position in Intellia Therapeutics during the third quarter worth approximately $18,077,000. GMT Capital Corp bought a new position in Intellia Therapeutics during the first quarter worth approximately $4,657,000. Alyeska Investment Group L.P. raised its position in Intellia Therapeutics by 300.0% in the fourth quarter. Alyeska Investment Group L.P. now owns 140,000 shares of the company’s stock worth $1,835,000 after buying an additional 105,000 shares in the last quarter. Finally, Acadian Asset Management LLC bought a new position in Intellia Therapeutics during the first quarter worth approximately $1,355,000.

About Intellia Therapeutics

Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.

5 Day Chart for NASDAQ:NTLA

Receive News & Stock Ratings for Intellia Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics Inc and related stocks with our FREE daily email newsletter.